Nathalie Clément
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nathalie Clément has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Barry J. Byrne
University of Florida
6 shared publications - Darin J. Falk
Pediatrics, University of Florida, Gainesville, FL
4 shared publications - Barry J. Byrne
University of Florida
3 shared publications Brian Cleaver
Powell Gene Therapy Center, College of Medicine, University of Florida, Gainesville, FL, USA
3 shared publicationsMark Potter
Department of Pediatrics, Powell Gene Therapy Center, University of Florida, 1200 Newell Drive, Academic Research Building, RG-187, Gainesville, FL 32610, USA
3 shared publications- Phillip A. Doerfler
Department of Hematology, St. Jude Children’s Research Hospital, Memphis, TN
3 shared publications
Latest Publications
- Open Access
- 25 December 2021
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 24, 154-170
Comparison of highly pure rAAV9 vector stocks produced in suspension by PEI transfection or HSV infection reveals striking quantitative and qualitative differences
- 25 December 2021
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 24, 154-170
Open AccessComparison of highly pure rAAV9 vector stocks produced in suspension by PEI transfection or HSV infection reveals striking quantitative and qualitative differences
- Open Access
- 1 June 2021
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 21, 1-13
NaCl and KCl mediate log increase in AAV vector particles and infectious titers in a specific/timely manner with the HSV platform
- 1 June 2021
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 21, 1-13
Open AccessNaCl and KCl mediate log increase in AAV vector particles and infectious titers in a specific/timely manner with the HSV platform
- Open Access
- 18 September 2019
- Published by Bentham Science Publishers Ltd. in Current Gene Therapy
- Vol. 19 (3) , 197-207
Reduction of Autophagic Accumulation in Pompe Disease Mouse Model Following Gene Therapy
Background:: Pompe disease is a fatal neuromuscular disorder caused by a deficiency in acid α-glucosidase, an enzyme responsible for glycogen degradation in the lysosome. Currently, the only approved treatment for Pompe disease is enzyme replacement therapy (ERT), which increases patient survival, but does not fully correct the skeletal muscle pathology. Skeletal muscle pathology is not corrected with ERT because low cation-independent mannose-6-phosphate receptor abundance and autophagic accumulation inhibits the enzyme from reaching the lysosome. Thus, a therapy that more efficiently targets skeletal muscle pathology, such as adeno-associated virus (AAV), is needed for Pompe disease.Objective:: The goal of this project was to deliver a rAAV9-coGAA vector driven by a tissue restrictive promoter will efficiently transduce skeletal muscle and correct autophagic accumulation.Methods:: Thus, rAAV9-coGAA was intravenously delivered at three doses to 12-week old Gaa-/- mice. 1 month after injection, skeletal muscles were biochemically and histologically analyzed for autophagy-related markers.Results:: At the highest dose, GAA enzyme activity and vacuolization scores achieved therapeutic levels. In addition, resolution of autophagosome (AP) accumulation was seen by immunofluorescence and western blot analysis of autophagy-related proteins. Finally, mice treated at birth demonstrated persistence of GAA expression and resolution of lysosomes and APs compared to those treated at 3 months.Conclusion:: In conclusion, a single systemic injection of rAAV9-coGAA ameliorates vacuolar accumulation and prevents autophagic dysregulation.
- 18 September 2019
- Published by Bentham Science Publishers Ltd. in Current Gene Therapy
- Vol. 19 (3) , 197-207
Open AccessReduction of Autophagic Accumulation in Pompe Disease Mouse Model Following Gene Therapy
Background:: Pompe disease is a fatal neuromuscular disorder caused by a deficiency in acid α-glucosidase, an enzyme responsible for glycogen degradation in the lysosome. Currently, the only approved treatment for Pompe disease is enzyme replacement therapy (ERT), which increases patient survival, but does not fully correct the skeletal muscle pathology. Skeletal muscle pathology is not corrected with ERT because low cation-independent mannose-6-phosphate receptor abundance and autophagic accumulation inhibits the enzyme from reaching the lysosome. Thus, a therapy that more efficiently targets skeletal muscle pathology, such as adeno-associated virus (AAV), is needed for Pompe disease.Objective:: The goal of this project was to deliver a rAAV9-coGAA vector driven by a tissue restrictive promoter will efficiently transduce skeletal muscle and correct autophagic accumulation.Methods:: Thus, rAAV9-coGAA was intravenously delivered at three doses to 12-week old Gaa-/- mice. 1 month after injection, skeletal muscles were biochemically and histologically analyzed for autophagy-related markers.Results:: At the highest dose, GAA enzyme activity and vacuolization scores achieved therapeutic levels. In addition, resolution of autophagosome (AP) accumulation was seen by immunofluorescence and western blot analysis of autophagy-related proteins. Finally, mice treated at birth demonstrated persistence of GAA expression and resolution of lysosomes and APs compared to those treated at 3 months.Conclusion:: In conclusion, a single systemic injection of rAAV9-coGAA ameliorates vacuolar accumulation and prevents autophagic dysregulation.
- 31 March 2019
- Published by Springer Nature
- p. 253-273
Large-Scale Clinical Manufacturing of AAV Vectors for Systemic Muscle Gene Therapy
- 31 March 2019
- Published by Springer Nature
- p. 253-273
Large-Scale Clinical Manufacturing of AAV Vectors for Systemic Muscle Gene Therapy
- 5 November 2018
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 20 (suppl_6) , vi202
PDCT-08. TRACKING THE T CELL REPERTOIRE AFTER ADOPTIVE CELL THERAPY IN PEDIATRIC PATIENTS WITH RECURRENT MEDULLOBLASTOMA
Adoptive cellular therapy (ACT) using transfer of tumor-specific lymphocytes is a promising way to treat tumor patients. Tumor-specific T cells can lead to tumor regression in some cancer patients who do not respond to other therapies; however, the ability to track these cells after transfer has remained limited. In this study, high-throughput deep sequencing was used to track the T cells after in vivo infusion in pediatric patients with central PNETs. Bulk peripheral blood mononuclear cells (PBMCs) are stimulated ex vivo using autologous DCs loaded with total tumor RNA. We used high-throughput T cell receptor sequencing to identify and track clones and their frequency in patients T cell isolates collected prior to adoptive cellular therapy and weekly for one month and then monthly following immunotherapy treatment. cDNA was generated with addition of a common adapter at 5 end of cDNA using RACE technology. A broad range of diversity was observed with 12772 to 33709 individual clones being identified in the different samples after ex vivo expansion. The most prevalent clone represented between 0.61 and 20% of the population depending on the patient. The patients with prolonged progression-free and overall survival maintained high frequency ex vivo expanded clonotypes for many months post infusion. We observed in these ex vivo-expanded samples significantly higher expression level of markers associated with long-lived memory T cells (CD27 and CD127) compared to short overall survival patients. In most patients, the clonal hierarchies in the ACT product did not correlate with the peak clonotype hierarchys post infusion suggesting considerable restructuring of T cell repertoire once product went in vivo. CONCLUSIONS: TCR deep sequencing can be used to quantitatively track ACT-derived T cells post infusion. Monitoring of TCR repertoire dynamics during ACT may provide an early biomarker for treatment response and clinical outcomes.
- 5 November 2018
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 20 (suppl_6) , vi202
PDCT-08. TRACKING THE T CELL REPERTOIRE AFTER ADOPTIVE CELL THERAPY IN PEDIATRIC PATIENTS WITH RECURRENT MEDULLOBLASTOMA
Adoptive cellular therapy (ACT) using transfer of tumor-specific lymphocytes is a promising way to treat tumor patients. Tumor-specific T cells can lead to tumor regression in some cancer patients who do not respond to other therapies; however, the ability to track these cells after transfer has remained limited. In this study, high-throughput deep sequencing was used to track the T cells after in vivo infusion in pediatric patients with central PNETs. Bulk peripheral blood mononuclear cells (PBMCs) are stimulated ex vivo using autologous DCs loaded with total tumor RNA. We used high-throughput T cell receptor sequencing to identify and track clones and their frequency in patients T cell isolates collected prior to adoptive cellular therapy and weekly for one month and then monthly following immunotherapy treatment. cDNA was generated with addition of a common adapter at 5 end of cDNA using RACE technology. A broad range of diversity was observed with 12772 to 33709 individual clones being identified in the different samples after ex vivo expansion. The most prevalent clone represented between 0.61 and 20% of the population depending on the patient. The patients with prolonged progression-free and overall survival maintained high frequency ex vivo expanded clonotypes for many months post infusion. We observed in these ex vivo-expanded samples significantly higher expression level of markers associated with long-lived memory T cells (CD27 and CD127) compared to short overall survival patients. In most patients, the clonal hierarchies in the ACT product did not correlate with the peak clonotype hierarchys post infusion suggesting considerable restructuring of T cell repertoire once product went in vivo. CONCLUSIONS: TCR deep sequencing can be used to quantitatively track ACT-derived T cells post infusion. Monitoring of TCR repertoire dynamics during ACT may provide an early biomarker for treatment response and clinical outcomes.
- Open Access
- 1 February 2017
- Published by SAGE Publications in Human Gene Therapy Methods
- Vol. 28 (1) , 1-14
Sodium Chloride Enhances Recombinant Adeno-Associated Virus Production in a Serum-Free Suspension Manufacturing Platform Using the Herpes Simplex Virus System
The increase in effective treatments using recombinant adeno-associated viral (rAAV) vectors has underscored the importance of scalable, high-yield manufacturing methods. Previous work from this group reported the use of recombinant herpes simplex virus type 1 (rHSV) vectors to produce rAAV in adherent HEK293 cells, demonstrating the capacity of this system and quality of the product generated. Here we report production and optimization of rAAV using the rHSV system in suspension HEK293 cells (Expi293F) grown in serum and animal component-free medium. Through adjustment of salt concentration in the medium and optimization of infection conditions, titers greater than 1 × 1014 vector genomes per liter (VG/liter) were observed in purified rAAV stocks produced in Expi293F cells. Furthermore, this system allowed for high-titer production of multiple rAAV serotypes (2, 5, and 9) as well as multiple transgenes (green fluorescent protein and acid α-glucosidase). A proportional increase in vector production was observed as this method was scaled, with a final 3-liter shaker flask production yielding an excess of 1 × 1015 VG in crude cell harvests and an average of 3.5 × 1014 total VG of purified rAAV9 material, resulting in greater than 1 × 105 VG/cell. These results support the use of this rHSV-based rAAV production method for large-scale preclinical and clinical vector production.
- 1 February 2017
- Published by SAGE Publications in Human Gene Therapy Methods
- Vol. 28 (1) , 1-14
Open AccessSodium Chloride Enhances Recombinant Adeno-Associated Virus Production in a Serum-Free Suspension Manufacturing Platform Using the Herpes Simplex Virus System
The increase in effective treatments using recombinant adeno-associated viral (rAAV) vectors has underscored the importance of scalable, high-yield manufacturing methods. Previous work from this group reported the use of recombinant herpes simplex virus type 1 (rHSV) vectors to produce rAAV in adherent HEK293 cells, demonstrating the capacity of this system and quality of the product generated. Here we report production and optimization of rAAV using the rHSV system in suspension HEK293 cells (Expi293F) grown in serum and animal component-free medium. Through adjustment of salt concentration in the medium and optimization of infection conditions, titers greater than 1 × 1014 vector genomes per liter (VG/liter) were observed in purified rAAV stocks produced in Expi293F cells. Furthermore, this system allowed for high-titer production of multiple rAAV serotypes (2, 5, and 9) as well as multiple transgenes (green fluorescent protein and acid α-glucosidase). A proportional increase in vector production was observed as this method was scaled, with a final 3-liter shaker flask production yielding an excess of 1 × 1015 VG in crude cell harvests and an average of 3.5 × 1014 total VG of purified rAAV9 material, resulting in greater than 1 × 105 VG/cell. These results support the use of this rHSV-based rAAV production method for large-scale preclinical and clinical vector production.
- Open Access
- 1 May 2016
- Published by Elsevier in Molecular Therapy
- Vol. 24, S186-S187
472. Evaluation of Re-Administration of a Recombinant Adeno-Associated Vector Expressing Acid-Alpha-Glucosidase (rAAV9-DES-hGAA) in Pompe Disease: Preclinical to Clinical Planning
- 1 May 2016
- Published by Elsevier in Molecular Therapy
- Vol. 24, S186-S187
Open Access472. Evaluation of Re-Administration of a Recombinant Adeno-Associated Vector Expressing Acid-Alpha-Glucosidase (rAAV9-DES-hGAA) in Pompe Disease: Preclinical to Clinical Planning
- Open Access
- 1 January 2016
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 3, 16031
A scalable method for the production of high-titer and high-quality adeno-associated type 9 vectors using the HSV platform
- 1 January 2016
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 3, 16031
Open AccessA scalable method for the production of high-titer and high-quality adeno-associated type 9 vectors using the HSV platform
- 4 November 2015
- Published by SAGE Publications in Human Gene Therapy
- Vol. 27 (1) , 43-59
Copackaged AAV9 Vectors Promote Simultaneous Immune Tolerance and Phenotypic Correction of Pompe Disease
Pompe disease is a progressive neuromuscular disorder caused by lysosomal accumulation of glycogen from a deficiency in acid alpha-glucosidase (GAA). Replacement of the missing enzyme is available by repeated protein infusions; however, efficacy is limited by immune response and inability to restore enzymatic function in the central nervous system. An alternative therapeutic option is adeno-associated virus (AAV)-mediated gene therapy, which results in widespread gene transfer and prolonged transgene expression. Both enzyme replacement therapy (ERT) and gene therapy can elicit anti-GAA immune reactions that dampen their effectiveness and pose life-threatening risks to patient safety. To modulate the immune responses related to gene therapy, we show that a human codon-optimized GAA (coGAA) driven by a liver-specific promoter (LSP) using AAV9 is capable of promoting immune tolerance in a Gaa −/− mouse model. Copackaging AAV9-LSP-coGAA with the tissue-restricted desmin promoter (AAV9-DES-coGAA) demonstrates the necessary cell autonomous expression in cardiac muscle, skeletal muscle, peripheral nerve, and the spinal cord. Simultaneous high-level expression in liver led to the expansion of GAA-specific regulatory T-cells (T regs ) and induction of immune tolerance. Transfer of T regs into naïve recipients prevented pathogenic allergic reactions after repeated ERT challenges. Copackaged AAV9 also attenuated preexisting humoral and cellular immune responses, which enhanced the biochemical correction. Our data present a therapeutic design in which simultaneous administration of two copackaged AAV constructs may provide therapeutic benefit and resolve immune reactions in the treatment of multisystem disorders.
- 4 November 2015
- Published by SAGE Publications in Human Gene Therapy
- Vol. 27 (1) , 43-59
Copackaged AAV9 Vectors Promote Simultaneous Immune Tolerance and Phenotypic Correction of Pompe Disease
Pompe disease is a progressive neuromuscular disorder caused by lysosomal accumulation of glycogen from a deficiency in acid alpha-glucosidase (GAA). Replacement of the missing enzyme is available by repeated protein infusions; however, efficacy is limited by immune response and inability to restore enzymatic function in the central nervous system. An alternative therapeutic option is adeno-associated virus (AAV)-mediated gene therapy, which results in widespread gene transfer and prolonged transgene expression. Both enzyme replacement therapy (ERT) and gene therapy can elicit anti-GAA immune reactions that dampen their effectiveness and pose life-threatening risks to patient safety. To modulate the immune responses related to gene therapy, we show that a human codon-optimized GAA (coGAA) driven by a liver-specific promoter (LSP) using AAV9 is capable of promoting immune tolerance in a Gaa −/− mouse model. Copackaging AAV9-LSP-coGAA with the tissue-restricted desmin promoter (AAV9-DES-coGAA) demonstrates the necessary cell autonomous expression in cardiac muscle, skeletal muscle, peripheral nerve, and the spinal cord. Simultaneous high-level expression in liver led to the expansion of GAA-specific regulatory T-cells (T regs ) and induction of immune tolerance. Transfer of T regs into naïve recipients prevented pathogenic allergic reactions after repeated ERT challenges. Copackaged AAV9 also attenuated preexisting humoral and cellular immune responses, which enhanced the biochemical correction. Our data present a therapeutic design in which simultaneous administration of two copackaged AAV constructs may provide therapeutic benefit and resolve immune reactions in the treatment of multisystem disorders.
- Open Access
- 1 May 2015
- Published by Elsevier in Molecular Therapy
- Vol. 23, S159
401. AAV Therapy Attenuates Respiratory Dysfunction and Glycogen Accumulation in a Murine Model of Glycogen Storage Disease Type II
- 1 May 2015
- Published by Elsevier in Molecular Therapy
- Vol. 23, S159
Open Access401. AAV Therapy Attenuates Respiratory Dysfunction and Glycogen Accumulation in a Murine Model of Glycogen Storage Disease Type II